CUV 1.85% $13.28 clinuvel pharmaceuticals limited

nomura "maa review should complete by start 4q, page-7

  1. 6 Posts.
    Southern, your posts clearly indicate knowledge and experience with biotechs, and are infinitely more informative than what I can offer. I strongly believe you are underestimating the Clinuvel team and the strategy they have layed out. The meticulous (to the point of nauseam) nature of their trials and analysis will pave the way to approval with the EMA. The timing of this will avoid dilution. The approval itself will simply crack the door on the availability of this drug, which Phillipe & co. will kick in with expediated Vitiligo trials, introduction of 9900 and pediatric trials and the inevitable off label use. All of this will lead to a multibillion dollar company in 3 years or so. Use charts and your experience if you like, but timing this game is foolish. The odds of making 20 times your money by 2016 are no better any where else, so wait and be rewarded.
 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
(20min delay)
Last
$13.28
Change
-0.250(1.85%)
Mkt cap ! $664.8M
Open High Low Value Volume
$13.55 $13.62 $13.25 $1.157M 86.45K

Buyers (Bids)

No. Vol. Price($)
1 227 $13.28
 

Sellers (Offers)

Price($) Vol. No.
$13.42 228 1
View Market Depth
Last trade - 16.10pm 15/11/2024 (20 minute delay) ?
CUV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.